CLINICAL_TRIALS
ClinicalTrials.gov record update
The Safety and Efficacy of Sintilimab Combined With Hypofractionated Radiotherapy in MSI-H/dMMR Rectal Cancer: a Prospective, Single-arm, Multicenter, Phase Ib Study
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04636008
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:18.548237+00:00
- Published At
- 2024-08-06T00:00:00+00:00
- Record Updated At
- 2024-08-06
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Anti-PD-1 Antibody", "Radiotherapy", "Rectal Cancer", "MSI-H", "Mmr Deficiency"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-08-06"- protocolSection.identificationModule.nctId
"NCT04636008"- protocolSection.identificationModule.officialTitle
"The Safety and Efficacy of Sintilimab Combined With Hypofractionated Radiotherapy in MSI-H/dMMR Rectal Cancer: a Prospective, Single-arm, Multicenter, Phase Ib Study"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.